18F-胆碱PET/CT检测高危分化型甲状腺癌结构性复发的作用
基于患者的分析显示,18F-FDG-PET/CT、18F-FCH-PET/CT及两者联合的灵敏度分别为69.6%、56.5%和82.6%,联合分析使4/23(17%)患者临床管理改变。
要点
- 18F-FCH-PET/CT可作为高危DTC随访的补充工具。
- 联合18F-FDG与18F-FCH可提高复发检出灵敏度至82.6%。
- Tg-DT<12个月与18F-FCH-PET/CT阳性显著相关。
核心结论
- 18F-FCH-PET/CT可能在高危DTC患者随访中提供重要信息。
- 对于非侵袭性DTC亚型、Tg-DT<12个月、高淋巴结转移风险且18F-FDG-PET/CT阴性或可疑的患者,18F-FCH-PET/CT可考虑作为有用的补充工具。
研究设计与样本
- 入组条件为促甲状腺激素抑制下甲状腺球蛋白高/升高、颈部超声阴性/不确定且131I全身扫描阴性。
- 所有患者在30天内先后接受18F-FDG-PET/CT和18F-FCH-PET/CT检查。
主要发现
- 23例患者确认存在DTC复发/持续。
- 基于患者分析,18F-FDG-PET/CT、18F-FCH-PET/CT及两者联合的灵敏度分别为69.6%、56.5%、82.6%,特异度均为100%,阴性预测值分别为22.2%、16.7%、33.3%,阳性预测值均为100%,准确率分别为72%、60%、84%。
- 与18F-FDG-PET/CT相比,联合分析使4/23(17%)患者的临床管理发生改变。
- 基于病灶分析,18F-FDG-PET/CT、18F-FCH-PET/CT及联合的灵敏度分别为58.7%、38.1%、66.7%;仅考虑淋巴结受累时分别为56.3%、53.1%、68.8%。
- 血清甲状腺球蛋白倍增时间(Tg-DT)<12个月与18F-FCH-PET/CT阳性显著相关;18F-FDG-PET/CT阳性与Tg-DT<12个月及DTC侵袭性亚型存在接近显著的关联趋势。
临床怎么用
- 在高危DTC患者随访中,当Tg升高但颈部超声和131I全身扫描阴性时,可考虑联合18F-FDG-PET/CT与18F-FCH-PET/CT以提高复发检出。
- 对于非侵袭性亚型、Tg-DT<12个月、高淋巴结转移风险且18F-FDG-PET/CT阴性或可疑者,18F-FCH-PET/CT可提供补充诊断信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to evaluate the role of 18F-choline (18F-FCH) positron emission tomography (PET)/computed tomography (CT) in high-risk differentiated thyroid cancer (DTC) patients with suspected relapse. It also compared 18F-FCH-PET/CT results with those of fludeoxyglucose (18F-FDG)-PET/CT and evaluated the additional diagnostic value and clinical impact of the combined use of these two tracers. Finally, it assessed the association between the clinical, biochemical, and histological parameters and 18F-FCH-PET/CT and 18F-FDG-PET/CT results. METHODS: The study prospectively enrolled high-risk DTC patients treated with thyroidectomy and radioactive iodine therapy and presenting high/increasing thyroglobulin levels under thyrotropin suppression, negative/inconclusive neck ultrasound, and negative 131I whole-body scan. All patients underwent 18F-FDG-PET/CT and 18F-FCH-PET/CT within 30 days of each other. Experienced nuclear medicine physicians examined the images of both procedures, and an integrated analysis of the two PET/CT modalities was also conducted. For each modality, a patient-based analysis (PBA) and lesion-based-analysis (LBA) was performed. On PBA, sensitivity, specificity, negative predictive value, positive predictive value, and accuracy were calculated. On LBA, only sensitivity was calculated. The standard of reference was based on clinical, imaging, and histological data. RESULTS: Twenty-five high-risk DTC patients were included; DTC relapse/persistence was confirmed in 23 patients. On PBA, 18F-FDG-PET/CT, 18F-FCH-PET/CT, and the integrated evaluation of the two imaging modalities showed the following rates: sensitivity, specificity, negative predictive value, positive predictive value, and accuracy were 69.6%, 100%, 22.2%, 100%, and 72% versus 56.5%, 100%, 16.7%, 100%, and 60% versus 82.6%, 100%, 33.3%, 100%, and 84%, respectively. When compared with 18F-FDG-PET/CT, the integrated analysis of these two imaging procedures changed the clinical management in 4/23 (17%) patients. On LBA, the sensitivity rates of 18F-FDG-PET/CT, 18F-FCH-PET/CT, and the combined evaluation of the two modalities were 58.7%, 38.1%, and 66.7%, respectively; when only lymph node involvement was considered, the rates were 56.3%, 53.1%, and 68.8%, respectively. Serum thyroglobulin doubling time (Tg-DT) <12 months was significantly associated with positive 18F-FCH-PET/CT. A trend toward a significant association was also found between positive 18F-FDG-PET/CT and both Tg-DT <12 months and DTC aggressive subtypes. CONCLUSION: 18F-FCH-PET/CT may add important information during the follow-up of high-risk DTC patients. 18F-FCH-PET/CT may be considered a useful complementary tool in patients affected by non-aggressive DTC subtypes, with Tg-DT <12 months, high risk of lymph node spreading, and negative or doubtful 18F-FDG-PET/CT.
引用
- Piccardo A, Trimboli P, Puntoni M, et al. Role of 18F-Choline Positron Emission Tomography/Computed Tomography to Detect Structural Relapse in High-Risk Differentiated Thyroid Cancer Patients. Thyroid. 2019. PMID: 30864903. doi:10.1089/thy.2018.0552
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。